Leadership Transition
Legend Biotech Corporation (NASDAQ: LEG N) disclosed that Chief Executive Officer Ying Huang will step down from both his executive role and the Board of Directors. Huang, who has led the company for seven years and overseen its evolution from a pioneering cell‑therapy developer to a commercial‑stage organization, will remain as an advisor through August to support the transition.
Interim Management Appointment
Effective July 24, the Board appointed Alan Bash, currently President of the CARVYKTI Business Unit, as Interim Chief Executive Officer. Bash brings commercial and operational experience within Legend and deep knowledge of the CARVYKTI program, which is the company’s CAR‑T cell therapy for relapsed or refractory multiple myeloma developed in collaboration with Johnson & Johnson. Bash said his immediate focus will be on ensuring continuity across the business and maintaining execution of commercial, clinical, and operational priorities.
Board Actions and Outlook
Chairman Frank Zhang expressed confidence in Bash’s ability to provide continuity during the transition period and announced that the Board has initiated a search process to identify a permanent successor. The company emphasized that its overall strategy and priorities remain unchanged.
Market Reaction and Analyst Update
Following the announcement, Legend Biotech shares fell 5.7% in pre‑market trading. RBC Capital analyst Leonid Timashev lowered the firm’s price target to $59.00 from $63.00 while maintaining an Outperform rating on the stock.
Company Profile
Legend Biotech employs over 3,000 people and is headquartered in Bridgewater, New Jersey. The firm focuses on developing and marketing CAR‑T cell therapies for cancer care, with its lead product CARVYKTI targeting multiple myeloma.